When More Is Less

Kuritzkes, Daniel R.
August 2004
Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p559
Academic Journal
Landmark studies on the dynamics of HIV-1 infection, conducted nearly a decade ago, provided the theoretical framework on which the modern approach to combination antiretroviral therapy is based. Against this background, AIDS Clinical Trials Group protocol 388 was designed to test the hypothesis that 4-drug regimens would be more efficacious than a standard 3-drug regimen in subjects with advanced HIV-1 disease and a limited history of prior antiretroviral treatment. Patients received a 3-drug regimen of zidovudine, lamivudine, and indinavir or a 4-drug regimen of zidovudine and lamivudine plus efavirenz and in dinavir or neffinavir and indinavir.


Related Articles

  • AIDS Vaccine Conference. Rockwood, Kate // Fast Company;Sep2011, Issue 158, p25 

    A timeline is presented of events following the first diagnosis of HIV 30 years ago, including the identification of the virus that causes AIDS, the first antiretroviral drug to become available for HIV treatment, called AZT, and the first phase III testing of an AIDS vaccine, AIDSVAX by VaxGen.

  • AZT and AIDS: the doubts persist. Brown, Phyllida // New Scientist;10/26/91, Vol. 132 Issue 1792, p20 

    Focuses on the concerns of medical scientists on the value of the AIDS drug zidovudine and its long-term side effects. Controversy surrounding the use of the drug for people with HIV infection but no symptoms of the disease; Ability of the drug to delay the progression of disease in some...

  • Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss. van Vonderen, Marit G. A.; van Agtmael, Michiel A.; Hassink, Elly A. M.; Milinkovic, Ana; Brinkman, Kees; Geerlings, Suzanne E.; Ristola, Matti; van Eeden, Arne; Danner, Sven A.; Reiss, Peter // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to determine whether zidovudine-sparing...

  • Antiretroviral Drug Resistance Testing: Potential Use following Nosocomial Exposure to HIV. Worthington, Michael // Clinical Infectious Diseases;12/15/2003, Vol. 37 Issue 12, p1722 

    The excellent summary of the 2003 recommendations of the International AIDS society, the U.S. panel on antiretroviral drug testing in adults did not mention the potential utility of resistance testing in guiding postexposure prophylaxis (PEP) following high-risk needlestick injury in health care...

  • Chapter 1: An Adult Infectious Disease Doctor's Encounter with HIV/AIDS. Berkman, Alan; Willinger, Barbara I.; Rice, Alan // History of AIDS Social Work in Hospitals: A Daring Response to a;2003, p3 

    Chapter 1 of the book "A History of AIDS Social Work in Hospitals: A Daring Response to an Epidemic" is presented. It explores the history of HIV/AIDS epidemic in the U.S. It cites several symptoms of AIDS including weight loss, diarrhea and a variety of sores. It provides information on several...

  • Perinatal transmission - successful interventions. Where do we go from here? Wilfert, M; Fleming, Thomas // International Journal of STD & AIDS;Dec1998 Supplement 1, Vol. 9, p22 

    The article discusses the efficacy of zidovudine (ZDV) in interrupting mother-to-infant transmission of HIV. Three large randomized controlled clinical trials were conducted by the AIDS Clinical Trial Group (ACTG). Results showed that ZDV administered during pregnancy, labor, delivery and to...

  • WHO releases new HIV recommendations.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p1 

    The article focuses on the guidelines issued by the World Health Organization (WHO) for the treatment and prevention of human immunodeficiency virus (HIV). WHO recommends the use of antiretroviral therapy (ART) from week 14 of pregnancy until the end of breastfeeding. It also suggests the use of...

  • GSK provides further aid in the fight against HIV/AIDS.  // PharmacoEconomics & Outcomes News;6/17/2006, Issue 505, p10 

    The article reports on the extension of GlaxoSmithKline's not-for-profit offer of antiretrovirals in developing countries via price reductions of three current medicines in the scheme, as well as the addition of two new treatments for human immunodeficiency virus (HIV) infections and AIDS. From...

  • What the HIV community thinks about when to start--and START. Jeffreys, Richard // Research Initiative/Treatment Action!;Autumn2008, Vol. 13 Issue 2, p46 

    The article focuses on the issues over Strategies for Timing of Antiretroviral Treatment (START) therapy in HIV patients. It says that the zidovudine or AZT's approval in 1987 has caused the issue of when to start the antiretroviral therapy (ART). It states the recommendation to start AZT...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics